Preparation of the enantiomerically enriched precursor of Lamivudine (cas 134678-17-4) (3TC™) via asymmetric catalysis mediated by Klebsiella oxytoca

Add time:07/31/2019    Source:sciencedirect.com

We report the asymmetric catalysis mediated by a newly isolated strain from soil, Klebsiella oxytoca, for the preparation of the chiral intermediate of antiviral agent Lamivudine (cas 134678-17-4) which is proven to be one of most potent medicines for the treatment of human chronic hepatitis B and HIV infection. To improve the efficiency of the transformation, firstly the carbon and nitrogen sources of the medium were screened and the best performance was achieved with glucose (5 g/L) as carbon source and tryptone (5 g/L) as nitrogen source. Secondly, optimization of the reaction condition was carried out. A series of parameters were investigated including temperature, pH, metal ions, surfactant, and substrate concentration. The best outcome [enantiomeric excess (ee) of 99.9% and yield of 24%] of the enantioselective resolution of the racemic substrate catalyzed by whole cell of Klebsiella oxytoca was reached at 30 ℃, pH 7.0, substrate concentration of 1.5 g/L, and no additives. As a comparation to most of the lipase-catalyzed systems for the production of chiral oxathiolane moiety of lamivudine, the reaction occurred in a single-phase aqueous system which meets the golden and stringent criteria of green chemistry. To our knowledge, this is the first study using Klebsiella oxytoca as catalyst for the preparation of the chiral moiety of lamivudine.

We also recommend Trading Suppliers and Manufacturers of Lamivudine (cas 134678-17-4). Pls Click Website Link as below: cas 134678-17-4 suppliers

Prev:Lamivudine (cas 134678-17-4) use in pregnant HBsAg-females effectively reduces maternal viremia
Next:Automated pre-column high-performance liquid chromatographic method for the investigation of Adibendan (cas 100510-33-6) metabolism)